![](https://bigul.co/stock-screener/assetData/img/bar-shape.png)
![](https://bigul.co/stock-screener/assetData/img/pointer.png)
Bullish Moving Averages
6
Bearish Moving Averages
10
Back Stocks profile
Open Price
87.40Prev. Close
85.4500Volume
989.00Value
86399.04Market Cap Cr
206.70
Price to Earnings
28.10
Price to Book Value
2.60
Dividend Yield
0.00
PE to Growth
-0.80
Op Revenue TTM Cr
152.47
Net Profit TTM Cr
7.35
Cash From Operating Activity Cr
9.48
Return on Equity %
9.08
EMA & SMA
Bullish Moving Averages
6
Bearish Moving Averages
10
DELIVERY AND VOLUME
02 Jul, 2024
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
PIVOT
First Resistance
83.20
Second Resistance
83.20
Third Resistance
83.20
First Support
83.20
Second Support
83.20
Third Support
83.20
Relative Strength Index
44.42
Money Flow Index
60.72
MACD
-2.11
MACD Signal
0.02
Average True Range
4.32
Average Directional Index
24.08
Rate of Change (21)
-4.91
Rate of Change (125)
-0.66
Commodity Channel Index
-59.7
Williams %R
-75
BETA
1 Month
0.19
3 Month
0.15
1 Year
-0.2
3 Year
-0.09
PRICE CHANGE ANALYSIS
1 Week
Low
High
79.24
87.36
1 Month
Low
High
73.25
87.36
3 Months
Low
High
73.25
113
6 Months
Low
High
73.25
113
1 Year
Low
High
73.25
119
BAFNA PHARMACEUTICALS LTD. - 532989 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations For Temporary Disruption Of Operations.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Temporary Disruption of operations at Manufacturing facility situated at Grantlyon, Chennai.BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window
Intimation for Closure of Trading Window.BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We hereby enclose the Newspaper Publication for the Audited Financial Results for the Quarter ended March 31, 2024 published in "Business Standard" (English) and "Makkal Kural" (Tamil) on May 31, 2024.BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Reg.24(A)-Annual Secretarial Compliance
We are herewith filing the Annual Secretarial Compliance Report for the financial year ended March 31, 2024.BAFNA PHARMACEUTICALS LTD. - 532989 - Appointment of Company Secretary and Compliance Officer
We hereby inform that the Board of Directors in their meeting held on May 29, 2024 has appointed Mr. A Mohanachandran as the Company Secretary & Compliance officer of the Company w.e.f May 29, 2024.BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 29/05/2024.
The Board of Directors in the meeting held on 29/05/2019 has inter-alia (i) approved the audited financial results of the Company for the quarter & year ended March 31, 2024; (ii) ii). Appointment of Mr. A. Mohanachandran, as the Company Secretary & Compliance Officer of the Company with effect from May 29, 2024BAFNA PHARMACEUTICALS LTD. - 532989 - Audited Financial Results Of The Company For The Quarter & Year Ended 31/03/2024
We are herewith submitting the Audited Financial Results for the Quarter & Year ended 31/03/2024BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2024
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 ,inter alia, to consider and approve Consideration and Approval of the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2024.BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement Regarding Inauguration Of New Quality Control Laboratory Of Company
We are delighted to announce the inauguration of new State-of-the-Art Quality Control Laboratory of the Company.BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Period Ended 31St March, 2024
We are herewith submitting the Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the period ended 31st March, 2024.The latest market price of Bafna Pharmaceuticals Ltd. on NSE was Rs. 87.36 as of today.
The opening share price of Bafna Pharmaceuticals Ltd. was Rs. 87.40 as of today.
The 52-week high share price of Bafna Pharmaceuticals Ltd. was Rs. 119.00.
The 52 week low share price of Bafna Pharmaceuticals Ltd. was Rs. 73.20.
Bafna Pharmaceuticals Ltd. has a market cap of Rs. 206.70 crore as of today. Please refer to the Fundamentals section for further details.
The PE ratio of Bafna Pharmaceuticals Ltd. is -0.80. Please refer to the Fundamentals section for further details.
The operating revenue for Bafna Pharmaceuticals Ltd. in the last FY was Rs. 152.47 crore. Please refer to the Financials section for further details.
The Net Profit for Bafna Pharmaceuticals Ltd. in the last FY was Rs. 7.35 crore. Please refer to the Financials section for further details.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
The latest dividend declared by Bafna Pharmaceuticals Ltd. was on 2013-09-19 for Rs. 0.6 per share. According to today’s share price, the dividend yield of Bafna Pharmaceuticals Ltd. stands at 0.00. Please refer to the Corporate Actions section for further details.
Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.
Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.
Please refer to the News section for the latest news about Bafna Pharmaceuticals Ltd..